Singh Sisters: Master’s, PhD & Postdoc Guidance | Study Abroad

Biogen’s Diranersen Shows 38% Slowing of Alzheimer’s Decline at Two Years

Biogen’s Diranersen Shows Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease

Results from the Phase 2 CELIA study suggest that diranersen, an investigational antisense oligonucleotide (ASO) targeting tau, continued to slow clinical decline in people with early Alzheimer’s disease over two years. The 60 mg twice-yearly regimen demonstrated a 38% slowing of decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), corresponding to a 1.09-point treatment difference at Week 96.

Biogen announced the findings on November 17, 2026, with data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference. The results add to growing interest in tau as a therapeutic target in Alzheimer’s disease and support further clinical investigation of approaches designed to reduce tau production.

Diranersen: An antisense approach to targeting tau

Tau is a protein that normally helps stabilise microtubules inside neurons. In Alzheimer’s disease, abnormal tau accumulation and aggregation are associated with neuronal dysfunction and disease progression.

Diranersen, also known as BIIB080, is an investigational antisense oligonucleotide designed to target the messenger RNA of the MAPT gene, which encodes tau. By reducing MAPT mRNA, the therapy aims to lower the production of all tau protein isoforms, potentially reducing both intracellular and extracellular tau.

Unlike therapeutic approaches that primarily target extracellular tau, diranersen is designed to reduce tau production at the RNA level.

The therapy was discovered by Ionis Pharmaceuticals. Biogen obtained a worldwide, exclusive, royalty-bearing licence to develop and commercialise diranersen in December 2019. In 2025, the US Food and Drug Administration (FDA) granted the investigational therapy Fast Track designation for Alzheimer’s disease.

What did the Phase 2 CELIA study investigate?

The global Phase 2 CELIA study evaluated the efficacy, safety and tolerability of diranersen in people with early Alzheimer’s disease.

The study enrolled 416 participants with either mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. Participants had not previously received anti-amyloid therapy.

The trial included three diranersen dosing regimens administered intrathecally:

  • 60 mg every six months
  • 115 mg every six months
  • 115 mg every three months

The placebo-controlled treatment period lasted 18 months. The primary endpoint was the dose response in change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory measures included cognitive and functional assessments, cerebrospinal fluid biomarkers and tau positron emission tomography (PET).

Two-year results show increasing treatment effects

The latest findings from the ongoing open-label extension (OLE) phase showed continued slowing of clinical decline across measures of cognition, daily functioning and disease progression.

The 60 mg twice-yearly regimen demonstrated the largest treatment effects at Week 96. Biogen reported a 38% slowing of clinical decline on CDR-SB, compared with 26% at Week 76.

The company also reported increasing treatment effects across several other clinical measures.

The CDR-SB result corresponded to a 1.09-point treatment difference at Week 96. According to Biogen, this exceeded the one-point difference that is generally considered highly meaningful by clinicians.

The results indicate a greater magnitude of treatment effect at two years on five of the six reported measures compared with 18 months. The MMSE measure showed a lower reported treatment effect at Week 96 (38%) than at Week 76 (50%).

Understanding the two-year analysis

An important consideration when interpreting these findings is the study design.

The two-year results were derived from the ongoing open-label extension of CELIA. The analysis compared participants who had received diranersen during the placebo-controlled phase and continued on the same dose through two years with participants who were initially assigned to placebo and subsequently transitioned into the extension phase.

By Week 96, participants in the original placebo group had received either no doses or a single dose of diranersen following their transition into the extension phase. This group therefore served as a placebo-equivalent comparator for the analysis.

Unlike the original 18-month placebo-controlled phase, the two-year comparison was not based on a fully placebo-controlled period. This distinction is important when assessing the strength of the findings and their implications for future clinical development.

Biomarker findings provide additional evidence of tau reduction

Alongside the two-year results, Biogen presented additional 18-month placebo-controlled clinical and biomarker findings.

In the 60 mg twice-yearly subgroup, diranersen demonstrated preferential effects in measures of memory, orientation and executive function.

The treatment also produced reductions in several tau-related biomarkers, including:

  • Tau PET signal across broad regions of the brain.
  • Cerebrospinal fluid phosphorylated tau 181 (CSF p-tau181).
  • Plasma phosphorylated tau 217 (plasma p-tau217).

These biomarker findings provide additional evidence that diranersen affects tau-related biology. However, changes in biomarkers and clinical outcomes represent different types of evidence; their relationship to long-term clinical benefit requires further investigation.

Safety and tolerability

According to Biogen, diranersen was generally well tolerated through two years, with no new safety signals observed.

Clinical benefits were reported across all doses studied, although the 60 mg twice-yearly regimen showed the largest treatment effects at two years and a favourable benefit–risk profile, according to the company.

Longer-term follow-up will be important to better understand the durability of the observed effects and the therapy’s safety profile.

What could this mean for people living with early Alzheimer’s disease?

Alzheimer’s disease is a progressive neurodegenerative condition that affects memory, thinking and the ability to perform everyday activities. Current research is exploring multiple disease-associated pathways, including amyloid-beta and tau pathology.

Diranersen represents an approach that targets tau production by reducing MAPT mRNA. The CELIA findings add to the evidence supporting tau as a potential therapeutic target and suggest that an RNA-targeting strategy may have the potential to influence clinical disease progression.

However, these findings should be interpreted in the context of the study’s Phase 2 design and open-label extension analysis. They do not yet establish that diranersen can provide sustained clinical benefit over longer periods or confirm its effectiveness in a larger population.

Diranersen remains investigational and has not been approved by any regulatory authority. Further evaluation in a Phase 3 clinical trial will be necessary to confirm its efficacy and safety.

The road ahead for tau-targeting therapies

The latest CELIA findings add an important development to the evolving landscape of Alzheimer’s disease research. While amyloid-targeting therapies have received considerable attention, tau remains an important therapeutic target because of its association with neuronal dysfunction and disease progression.

By targeting MAPT mRNA and reducing the production of tau protein, diranersen represents a distinct therapeutic strategy. Its continued clinical development could help researchers better understand whether reducing tau production can translate into meaningful and sustained benefits for people living with early Alzheimer’s disease.

The ongoing long-term extension study will continue to evaluate the safety, tolerability and durability of diranersen’s clinical effects.

Read the announcement: Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease

More Biopharma news

Related Articles

Subscribe to Newsletter

SciFocus Newsletter by BioPatrika